- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01061684
NAFLD Pediatric Database 2 (NAFLD Peds DB2)
February 7, 2022 updated by: Johns Hopkins Bloomberg School of Public Health
Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Database 2
The NAFLD Database 2 will recruit at least 650 new pediatric participants with liver biopsies and contemporaneous biosamples, and will also invite pediatric participants from the prior NAFLD Database and TONIC trial (50 with a recent biopsy and 150 without a contemporaneous biopsy) to enroll in the NAFLD Pediatric Database 2 study.
Combining the new and continuing participants leads to a recruitment goal for the pediatric Database 2 of 850 pediatric participants during the enrollment period.
Study Overview
Status
Completed
Conditions
Detailed Description
All the new pediatric participants will have had a liver biopsy within 120 days prior to enrollment coupled with contemporaneous biosamples within 90 days prior to enrollment and up to 90 days before or 4-90 days after the biopsy.
We estimate that at least 50 of the continuing pediatric participants will be due for a standard of care liver biopsy at the time of their enrollment into the pediatric Database 2 study, and will, as a result, also have a liver biopsy and contemporaneous biosamples.
Study Type
Observational
Enrollment (Actual)
969
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92103
- University of California, San Diego
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Ann & Robert H. Lurie Children's Hospital of Chicago (NWU)
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104
- St. Louis University
-
-
New York
-
Buffalo, New York, United States, 14222
- University at Buffalo-Women and Children's Hospital of Buffalo
-
New York, New York, United States, 10032
- Columbia University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital- UW
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants at least 2 years of age and less than 18 years of age with known or suspected NAFLD or NASH-related cirrhosis
Description
Inclusion Criteria:
Continuing participants:
- Previously enrolled in the NAFLD Database study or TONIC trial
- Age at least 2 years and not older than 17 years during the consent process
- Willingness to continue to be followed for up to 4 years
- Ability and willingness to give written, informed parental consent and child assent, per local IRB guidelines, to be enrolled into the pediatric Database 2 study
New participants:
- Age at least 2 years of age and not older than 17 years during the consent process
- Willingness to be followed for up to 4 years
- Ability and willingness to give written, informed parent consent and child assent to be enrolled into the pediatric Database 2 study
- Minimal or no alcohol use history consistent with NAFLD
- Having undergone a liver biopsy that is obtained within 120 days of enrollment
- Collection of biosamples (serum, plasma, DNA, and, if available, liver tissue) within 90 days prior to enrollment and 0-90 days before or 4-90 days after the standard of care liver biopsy
Exclusion Criteria:
- Total parenteral nutrition for more than 1 month within a 6 month period before baseline liver biopsy
- Short bowel syndrome
- History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric surgery performed following enrollment is not exclusionary. Liver biopsies obtained during bariatric surgery cannot be used for enrollment because of the associated surgical or anesthetic acute changes and the weight loss efforts that precede bariatric surgery
- History of biliopancreatic diversion
- Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score equal to or greater than 10
- Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (participants with isolated antibody to hepatitis B core antigen, anti-HBc total, are not excluded)
- Evidence of chronic hepatitis C as marked by the presence of anti-HCV or HCV RNA in serum
- Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of the investigator)
- Wilson's disease
- Known glycogen storage disease
- Known dysbetalipoproteinemia
- Known phenotypic hemochromatosis (HII greater than 1.9 or removal of more than 4 g of iron by phlebotomy)
- Prominent bile duct injury (florid duct lesions or periductal sclerosis) or bile duct paucity
- Chronic cholestasis
- Vascular lesions (vasculitis, cardiac sclerosis, acute or chronic Budd-Chiari, hepatoportal sclerosis, peliosis)
- Iron overload greater than 3+
- Zones of confluent necrosis, infarction, massive or sub-massive, pan-acinar necrosis
- Multiple epithelioid granulomas
- Congenital hepatic fibrosis
- Cystic fibrosis
- Polycystic liver disease
- Other metabolic or congenital liver disease
- Evidence of systemic infectious disease
- Known HIV positive
- Disseminated or advanced malignancy
- Concomitant severe underlying systemic illness that in the opinion of the investigator would interfere with completion of follow-up
- Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements
- Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of study
- Inability for parent to provide informed consent and child 8 years or greater to give assent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
NAFLD
pediatric patients with non-alcoholic fatty liver disease (NAFLD).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liver histology scores
Time Frame: varies
|
Liver histology scores (derived from central reading of liver biopsy at entry, standard of care biopsy done during screening or follow-up, or liver biopsy obtained for the TONIC trial)
|
varies
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Rausch JC, Lavine JE, Chalasani N, Guo X, Kwon S, Schwimmer JB, Molleston JP, Loomba R, Brunt EM, Chen YI, Goodarzi MO, Taylor KD, Yates KP, Rotter JI; NASH Clinical Research Network. Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2018 May;66(5):789-796. doi: 10.1097/MPG.0000000000001926.
- Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A; NASH Clinical Research Network. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr. 2014 Apr;164(4):707-713.e3. doi: 10.1016/j.jpeds.2013.10.071. Epub 2013 Dec 19.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2010
Primary Completion (Actual)
May 31, 2020
Study Completion (Actual)
May 31, 2020
Study Registration Dates
First Submitted
February 2, 2010
First Submitted That Met QC Criteria
February 2, 2010
First Posted (Estimate)
February 3, 2010
Study Record Updates
Last Update Posted (Actual)
February 23, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NAFLD Pediatric Database 2
- U01DK061730 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data will be uploaded to www.niddkrepository.org at the end of the funding.
IPD Sharing Time Frame
Data will become available once the funding cycle ends.
IPD Sharing Access Criteria
Access requires registration and approval from the NIDDK Repository.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Assistance Publique - Hôpitaux de ParisCompletedNonalcoholic Fatty Liver Disease (NAFLD)France
-
Massachusetts General HospitalCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Columbia UniversityGlaxoSmithKlineCompletedNon-Alcoholic Fatty Liver DiseaseUnited States
-
Kowa Company, Ltd.CompletedNon-Alcoholic Fatty Liver DiseaseJapan
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingMetabolic Associated Fatty Liver Disease | Clinical FeaturesChina
-
Chinese PLA General HospitalCompletedMetabolic-dysfunction-associated Fatty Liver Disease (MAFLD)China
-
University of L'AquilaRecruitingNAFLD- Non Alcoholic Fatty Liver DiseaseItaly